贝伐珠-话题@MedSci

#贝伐珠#

101篇内容 | 2880人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954815, encodeId=c0ad1954815de, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, objectType=article, longId=180959, objectId=d44c18095907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44c18095907, replyNumber=0, likeNumber=57, createdTime=2020-08-21, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44c18095907, moduleTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44c18095907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954820, encodeId=ad50195482042, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=阿特珠单抗联合贝伐珠能显著改善患者生存质量（IMbrave150研究）, objectType=article, longId=191288, objectId=43df19128885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43df19128885, replyNumber=0, likeNumber=93, createdTime=2021-03-11, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43df19128885, moduleTitle=阿特珠单抗联合贝伐珠能显著改善患者生存质量（IMbrave150研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43df19128885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954816, encodeId=03dd195481609, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, objectType=article, longId=181068, objectId=1eae18106814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eae18106814, replyNumber=0, likeNumber=88, createdTime=2020-06-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eae18106814, moduleTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eae18106814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954817, encodeId=157a195481ed2, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=国内贝伐珠单抗生物类似药获批上市, objectType=article, longId=184478, objectId=fb2a1844e82e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb2a1844e82e, replyNumber=0, likeNumber=61, createdTime=2020-09-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb2a1844e82e, moduleTitle=国内贝伐珠单抗生物类似药获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb2a1844e82e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954812, encodeId=f4451954812aa, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=重磅！贝伐珠单抗适应症扩展获批!, objectType=article, longId=153397, objectId=9c6815339e85, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c6815339e85, replyNumber=0, likeNumber=68, createdTime=2019-07-27, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c6815339e85, moduleTitle=重磅！贝伐珠单抗适应症扩展获批!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c6815339e85)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954814, encodeId=b5961954814b7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存, objectType=article, longId=174675, objectId=e49b1e46756a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e49b1e46756a, replyNumber=0, likeNumber=113, createdTime=2019-12-17, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e49b1e46756a, moduleTitle=JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e49b1e46756a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954813, encodeId=9c29195481306, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JCO：氟嘧啶、伊立替康和贝伐珠单抗序贯治疗vs初始三药联合用于转移性结直肠癌孰优孰劣？, objectType=article, longId=159714, objectId=8fb6159e1401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb6159e1401, replyNumber=0, likeNumber=78, createdTime=2019-09-01, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb6159e1401, moduleTitle=JCO：氟嘧啶、伊立替康和贝伐珠单抗序贯治疗vs初始三药联合用于转移性结直肠癌孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fb6159e1401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954808, encodeId=ad8219548089a, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究, objectType=article, longId=129855, objectId=efd412985541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efd412985541, replyNumber=0, likeNumber=77, createdTime=2019-01-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efd412985541, moduleTitle=Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efd412985541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954811, encodeId=4d27195481157, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, objectType=article, longId=146653, objectId=33e41466537f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e41466537f, replyNumber=0, likeNumber=85, createdTime=2019-05-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e41466537f, moduleTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e41466537f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954810, encodeId=1cd1195481070, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, objectType=article, longId=144371, objectId=70851443e128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70851443e128, replyNumber=0, likeNumber=75, createdTime=2019-05-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70851443e128, moduleTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70851443e128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954809, encodeId=874d19548094f, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JCO：贝伐珠单抗治疗转移性结直肠癌患者的生存预测标记物, objectType=article, longId=139192, objectId=3c1e139192e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c1e139192e1, replyNumber=0, likeNumber=84, createdTime=2019-04-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c1e139192e1, moduleTitle=JCO：贝伐珠单抗治疗转移性结直肠癌患者的生存预测标记物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c1e139192e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954805, encodeId=bde2195480545, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J AAPOS：单侧贝伐珠单抗治疗对于早产儿视网膜病变的黄斑形态影响！, objectType=article, longId=120599, objectId=61fa120599fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61fa120599fb, replyNumber=0, likeNumber=66, createdTime=2018-02-12, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61fa120599fb, moduleTitle=J AAPOS：单侧贝伐珠单抗治疗对于早产儿视网膜病变的黄斑形态影响！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61fa120599fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954801, encodeId=5698195480126, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？, objectType=article, longId=97609, objectId=1d9b9e609be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9b9e609be, replyNumber=0, likeNumber=0, createdTime=2018-04-07, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9b9e609be, moduleTitle=J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9b9e609be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954803, encodeId=52981954803ca, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JAMA Oncol：三个2带一个王：三药联合贝伐珠单抗，肠癌肝转移手术可以行, objectType=article, longId=105936, objectId=6fe81059367e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fe81059367e, replyNumber=0, likeNumber=69, createdTime=2018-02-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fe81059367e, moduleTitle=JAMA Oncol：三个2带一个王：三药联合贝伐珠单抗，肠癌肝转移手术可以行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fe81059367e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954807, encodeId=fba3195480ede, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Clin Oncol：转移性结直肠癌诱导治疗后的无化疗间期，是否应该采用贝伐珠单抗维持？, objectType=article, longId=128085, objectId=f5581280856f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5581280856f, replyNumber=0, likeNumber=76, createdTime=2018-02-08, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5581280856f, moduleTitle=J Clin Oncol：转移性结直肠癌诱导治疗后的无化疗间期，是否应该采用贝伐珠单抗维持？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5581280856f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954806, encodeId=1c2519548066c, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=N Engl J Med：多学科讨论：贝伐珠单抗为洛莫司汀治疗胶质母细胞瘤锦上添花？, objectType=article, longId=124733, objectId=95a8124e3311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95a8124e3311, replyNumber=0, likeNumber=72, createdTime=2018-01-18, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95a8124e3311, moduleTitle=N Engl J Med：多学科讨论：贝伐珠单抗为洛莫司汀治疗胶质母细胞瘤锦上添花？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95a8124e3311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954802, encodeId=2f5d1954802b6, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Ann Oncol：贝伐珠单抗可显著提高卵巢癌患者生存率！, objectType=article, longId=98196, objectId=2ddb98196c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ddb98196c2, replyNumber=0, likeNumber=76, createdTime=2018-03-07, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ddb98196c2, moduleTitle=Ann Oncol：贝伐珠单抗可显著提高卵巢癌患者生存率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ddb98196c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954804, encodeId=6a10195480455, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, objectType=article, longId=108199, objectId=19871081992f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19871081992f, replyNumber=0, likeNumber=69, createdTime=2017-10-11, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19871081992f, moduleTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19871081992f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954800, encodeId=a7ad1954800a5, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), objectType=article, longId=76991, objectId=b8c4e6991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8c4e6991d8, replyNumber=0, likeNumber=71, createdTime=2017-08-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8c4e6991d8, moduleTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8c4e6991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954799, encodeId=338b1954e99c8, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=SABCS 2015：贝伐珠单抗新辅助治疗能显著提高BRCA突变的三阴性乳腺癌pCR率，但DFS改善有限（GeparQuinto研究）, objectType=article, longId=60903, objectId=a15260903be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a15260903be, replyNumber=0, likeNumber=71, createdTime=2016-01-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a15260903be, moduleTitle=SABCS 2015：贝伐珠单抗新辅助治疗能显著提高BRCA突变的三阴性乳腺癌pCR率，但DFS改善有限（GeparQuinto研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a15260903be)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐珠

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准

2020-08-21

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

阿特珠单抗联合贝伐珠能显著改善患者生存质量（IMbrave150研究）

2021-03-11

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率

2020-06-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

国内贝伐珠单抗生物类似药获批上市

2020-09-06

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

重磅！贝伐珠单抗适应症扩展获批!

2019-07-27

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存

2019-12-17

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JCO：氟嘧啶、伊立替康和贝伐珠单抗序贯治疗vs初始三药联合用于转移性结直肠癌孰优孰劣？

2019-09-01

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lung Cancer：阿法替尼联合贝伐珠单抗治疗EGFR突变NSCLC的Ⅰ期研究

2019-01-15

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？

2019-05-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑

2019-05-06

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JCO：贝伐珠单抗治疗转移性结直肠癌患者的生存预测标记物

2019-04-13

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J AAPOS：单侧贝伐珠单抗治疗对于早产儿视网膜病变的黄斑形态影响！

2018-02-12

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？

2018-04-07

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JAMA Oncol：三个2带一个王：三药联合贝伐珠单抗，肠癌肝转移手术可以行

2018-02-05

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Clin Oncol：转移性结直肠癌诱导治疗后的无化疗间期，是否应该采用贝伐珠单抗维持？

2018-02-08

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

N Engl J Med：多学科讨论：贝伐珠单抗为洛莫司汀治疗胶质母细胞瘤锦上添花？

2018-01-18

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Ann Oncol：贝伐珠单抗可显著提高卵巢癌患者生存率！

2018-03-07

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗

2017-10-11

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3)

2017-08-13

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

SABCS 2015：贝伐珠单抗新辅助治疗能显著提高BRCA突变的三阴性乳腺癌pCR率，但DFS改善有限（GeparQuinto研究）

2016-01-06

科室
- - 订阅+
  - 更多科室
工具
服务